Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders
- 1 December 2019
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 24 (12) , 2307-2314
Abstract
No abstract availableKeywords
Funding Information
- Alzheimer's Research UK (ARUK-RF2018C-005)
- National Institute for Health Research
This publication has 73 references indexed in Scilit:
- Low levels of muscarinic M1 receptor–positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophreniaJournal of Psychiatry and Neuroscience, 2018
- Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson diseaseNeurology, 2018
- The distribution of muscarinic M1 receptors in the human hippocampusJournal of Chemical Neuroanatomy, 2016
- Genetic dissection of medial habenula–interpeduncular nucleus pathway function in miceFrontiers in Behavioral Neuroscience, 2013
- Topographical Organization of the Pedunculopontine NucleusFrontiers in Neuroanatomy, 2011
- CENTRAL CHOLINERGIC SYSTEMS AND COGNITIONAnnual Review of Psychology, 1997
- Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer diseaseProceedings of the National Academy of Sciences, 1996
- Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervationJournal of Neuroscience, 1995
- Chapter 26 Human brain cholinergic pathways1990
- Acetylcholinesterase-rich projections from the basal forebrain of the rhesus monkey to neocortexBrain Research, 1976